Health & Biotech
Incannex Healthcare Limited (IHL.ASX) is a clinical stage pharmaceutical development company developing unique medicinal cannabis pharmaceutical products and psychedelic medicine therapies for the treatment of Generalised Anxiety Disorder (GAD), Obstructive Sleep Apnoea (OSA), Traumatic Brain Injury (TBI)/Concussion, rheumatoid arthritis, inflammatory bowel disease and inflammatory lung conditions (ARDS, COPD, Asthma, Bronchitis).
FDA registration and marketing approval, subject to ongoing clinical success, is being pursued for each product and therapy under development.
Each indication represents major global markets and currently have either no, or limited, existing registered pharmacotherapy (drug) treatments available to the public, raising the possibility of patients receiving Government subsidies for products that demonstrate suitable safety and efficacy profiles in clinical trials.
Incannex has a strong patent filing strategy as it develops its products and therapies in conjunction with its medical and scientific advisory board and its collaborative partners, including Monash University and The Alfred Hospital.
KEY PEOPLE
RELATED STOCKHEAD STORIES
Health & Biotech
Weed Week: Social media platforms scramble to update advertising policies on cannabis products
News
Market Highlights: Wall Street rallies after soft US CPI; Elon Musk announces a new AI company
Health & Biotech
How Bod Science pulled ahead in the race for Australia’s first over-the-counter CBD
Health & Biotech
Incannex plans to redomicile to US with sole NASDAQ listing – we look at the arithmetic
Health & Biotech
ASX Health Stocks: Bod Science provides ‘landmark update’, while Incannex prepares to list on Nasdaq
Health & Biotech
ASX Health Stocks: Imricor jumps 13pc after funding deal; Louie the Beagle passes 1-year mark taking PharmAust’s drug
News
Market Highlights: ASX to fall, Meta to launch ‘Twitter killer’, and Franklin Templeton says “don’t sell’
Health & Biotech
Which ASX health companies are making strides in world’s largest healthcare market?
Health & Biotech
Incannex confident in upcoming pivotal study of IHL-42X drug into obstructive sleep apnoea
Health & Biotech
ASX-listed Zelira is going head-to-head with Big Pharma. We spoke to its CEO about its place in a US$62 billion market
Health & Biotech
Incannex appoints experienced lead investigators for Phase-2/3 clinical trial into sleep apnoea
Health & Biotech
Weed Week: A ‘shroom boom’ could see psychedelics follow cannabis’ explosive footsteps
Health & Biotech
World renowned psychedelics experts join Incannex’s Clarion Clinics advisory board
Stockhead TV
90 Seconds With…..Peter Widdows, Incannex (ASX:IHL)
Health & Biotech
Incannex’s subsidiary to open multiple psychedelic clinics to capture wide open opportunity
Mining
In Case You Missed It: Rare earth riches are enjoying their time in the sun
Health & Biotech